VBI Vaccines Announces Dosing of First Recurrent GBM Patient in Part B of Ongoing Phase 1/2a Study of VBI-1901

NEXT STORY
Turning Point Therapeutics Appoints Biotechnology Investment Banker Yi Larson as Executive Vice President and Chief Financial Officer
PREV STORY
Plus Therapeutics, Inc. Announces Nasdaq Ticker Symbol Changes and Reverse Stock Split
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

G1 Therapeutics Expands Executive Leadership Team with Appointment of John Demaree as Chief Commercial Officer and Stillman Hanson as General Counsel

RESEARCH TRIANGLE PARK, N.C., July 09, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:GTHX), ...

author_avatar
NASDAQ Market News

ASLAN Pharmaceuticals to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference 2020

author_avatar
NASDAQ Market News

New to The Street TV Announces its Five Corporate Interviews Airing on Fox Business Network, Tonight, Monday, October 18, 2021, at 10:30 PM P.T. and Tomorrow Night, Tuesday, October 19, 2021, at 10:30 PM PT

author_avatar
NASDAQ Market News